<DOC>
	<DOCNO>NCT00232869</DOCNO>
	<brief_summary>The main objective study assess safety performance sirolimus coat Cordis SMART™ nitinol self expandable stent device delivery system treatment obstructive superficial femoral artery ( SFA ) disease reduce percent in-stent mean lumen diameter stenosis de novo restenotic native lesion compare uncoated SMART™ stent .</brief_summary>
	<brief_title>A Study SMART Stent Treatment SFA Disease .</brief_title>
	<detailed_description>This multi-center , prospective , randomize , double blind , two-arm feasibility study evaluate safety performance sirolimus coat Cordis SMART™ nitinol self-expanding stent delivery system compare uncoated SMART™ stent delivery system . It anticipate total 90 patient enter study . Patients randomize 1:1 basis coat uncoated stent . Ninety ( 90 ) patient de novo restenotic native SFA lesion randomize Sirolimus Coated SMART™ nitinol self-expanding stent uncoated ( bare ) SMART™ stent . Patients follow 24 month post-procedure , patient duplex ultrasound clinical assessment discharge , 1 , 6 , 9 , 18 24 month , angiography 6 six month plain X-ray 18 month . This study conduct nine investigational site . ( Protocol amend 56 additional patient recruit follow 5 year . )</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . One superficial femoral artery present &gt; 70 % stenosis ( e ) total occlusion 2 . Symptomatic leg ischemia Rutherford Classification ( category 1 , 2 , 3 4 ) 1 . Tissue loss due ischemic disease ( Rutherford category 5 6 ) . 2 . Tandem lesion require non overlap stent ;</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>